News and reporting on HER2 biomarkers.
Puma provided an update on its plan for Nerlynx and Natera discussed the cancer trials its Signatera test is being used in.
Acepodia's off-the-shelf cell therapy uses an antibody-cell conjugate to target human HER2-expressing solid tumors.
Enhertu received accelerated approval based on data from a Phase II trial that reported a 60 percent overall response rate.
In a randomized trial, tucatinib with chemotherapy improved progression-free survival in patients with locally advanced or metastatic breast cancer.
Investigators at the San Antonio Breast Cancer Symposium reported median progression free survival of 16.4 months for those who got the target dose of the drug.
Investigators provided updated evidence that that the combined treatment prevents more women from relapsing, especially higher-risk node-positive patients.
Roche noted that it expects the European Commission to approve trastuzumab emtansine in the near future, based on the EMA committee's recommendation.
The data add to growing evidence supporting the use of HER2 therapy across solid tumors, though researchers find a difficult path to a tissue-agnostic approval.
A collection of biomarker- and genomic testing-driven precision oncology research presented at the European Society of Medical Oncology Congress.
Two studies showed that the addition of abemaciclib or ribociclib to fulvestrant improved overall survival in HR-positive, HER2-negative breast cancer patients.